Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Transitional Pneumovax Program for Age 70 and Up Set to End in March
A health ministry panel agreed on December 1 to wind up a transitional measure related to the vaccination of MSD’s 23-valent pneumococcal vaccine Pneumovax in the elderly aged 70 and older at the end of this fiscal year through March,…
To read the full story
Related Article
- Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
February 13, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- Health Ministry Panel OKs Inclusion of 5-in-1 Jab in NIP from Next April
December 21, 2023
- MHLW Panel OKs 5-Year Extension of Pneumovax Transitional Measure
January 11, 2019
- MHLW Panel to Discuss Changing Current Transitional Period for Pneumococcal Vaccinations in Elderly
November 2, 2018
- MHLW Presents Schedule for Discussions on Inclusion of 6 Vaccines in Public Vaccination Programs
May 21, 2018
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
REGULATORY
- Japan Approves MSD’s HIV Combo Idvynso
March 9, 2026
- MHLW Updates Elective Care LLP List; Target Products Down Sharply to 776
March 9, 2026
- MHLW Orders Label Revisions for Cancer Drugs, Anticoagulant over Bleeding Risk
March 9, 2026
- Japan Health Minister Lauds Approval of iPSC-Based Therapies
March 9, 2026
- Avastin Price to Be Axed by 45% as G1 Rule Hits Originator Biologics
March 6, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…